The dose that got you here and the dose that keeps you here
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
Pricing
Page 12 of 25 of this archive, newest first.
What TRIUMPH-1 tells us about maintenance, and what it does not
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
Two-thirds back: the extension nobody expected to be the headline
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
From the floor in Hangzhou: 4 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
From the floor in Nantong: 13 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The shortage years, and what they taught about interruption
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Singapore declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
From the floor in Shenzhen: 9 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Denmark declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The Netherlands caps tirzepatide prescribing to 4 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Italy caps semaglutide prescribing to 18 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
From the floor in Hong Kong: 13 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the pharmacokinetics permit and what they cannot tell you
A great deal of practice has grown up around intermittent schedules. The randomised evidence for any of them is, as far as the Journal can establish, nil.
Sweden caps liraglutide prescribing to 10 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
What TRIUMPH-1 tells us about maintenance, and what it does not
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
What STEP 8 tells us about maintenance, and what it does not
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
From the floor in Qingdao: 3 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.